JP2022514354A5 - - Google Patents
Info
- Publication number
- JP2022514354A5 JP2022514354A5 JP2021535554A JP2021535554A JP2022514354A5 JP 2022514354 A5 JP2022514354 A5 JP 2022514354A5 JP 2021535554 A JP2021535554 A JP 2021535554A JP 2021535554 A JP2021535554 A JP 2021535554A JP 2022514354 A5 JP2022514354 A5 JP 2022514354A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025183107A JP2026021440A (ja) | 2018-12-20 | 2025-10-30 | がん治療のための治療用ペプチドに関する方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782690P | 2018-12-20 | 2018-12-20 | |
| US62/782,690 | 2018-12-20 | ||
| PCT/US2019/067890 WO2020132465A1 (en) | 2018-12-20 | 2019-12-20 | Methods and compositions related to therapeutic peptides for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025183107A Division JP2026021440A (ja) | 2018-12-20 | 2025-10-30 | がん治療のための治療用ペプチドに関する方法および組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022514354A JP2022514354A (ja) | 2022-02-10 |
| JP2022514354A5 true JP2022514354A5 (https=) | 2022-12-06 |
| JPWO2020132465A5 JPWO2020132465A5 (https=) | 2022-12-06 |
| JP7773195B2 JP7773195B2 (ja) | 2025-11-19 |
Family
ID=71101609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535554A Active JP7773195B2 (ja) | 2018-12-20 | 2019-12-20 | がん治療のための治療用ペプチドに関する方法および組成物 |
| JP2025183107A Pending JP2026021440A (ja) | 2018-12-20 | 2025-10-30 | がん治療のための治療用ペプチドに関する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025183107A Pending JP2026021440A (ja) | 2018-12-20 | 2025-10-30 | がん治療のための治療用ペプチドに関する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3897669A4 (https=) |
| JP (2) | JP7773195B2 (https=) |
| CN (2) | CN113677351B (https=) |
| AU (1) | AU2019403393B2 (https=) |
| CA (1) | CA3123853A1 (https=) |
| WO (1) | WO2020132465A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4199947A4 (en) | 2020-08-18 | 2024-10-16 | Onchilles Pharma, Inc. | Modified porcine pancreatic elastase proteins |
| WO2022056488A1 (en) * | 2020-09-14 | 2022-03-17 | Genprex, Inc. | Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP1178817A2 (en) * | 1999-05-14 | 2002-02-13 | Arbor Vita Corporation | Molecular interactions in haematopoietic cells |
| US7608413B1 (en) * | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| WO2008067305A2 (en) * | 2006-11-28 | 2008-06-05 | Giic Research Development Corporation | Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain |
| ES2523992T3 (es) * | 2006-12-28 | 2014-12-03 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo |
| JP6153526B2 (ja) * | 2011-09-06 | 2017-06-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | ポリペプチドワクチン |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| BR112015008612A2 (pt) * | 2012-10-17 | 2017-09-26 | Vascular Biogenics Ltd | métodos de tratamento utilizando adenovirus |
| WO2014118643A2 (en) * | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| GB201506223D0 (en) * | 2015-04-13 | 2015-05-27 | Ucl Business Plc | Chimeric protein |
| WO2018073394A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| EP4292606B1 (en) * | 2017-06-15 | 2025-11-12 | The University of Chicago | Compositions for treating cancer |
| WO2019051001A1 (en) * | 2017-09-06 | 2019-03-14 | California Institute Of Technology | SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR) |
-
2019
- 2019-12-20 AU AU2019403393A patent/AU2019403393B2/en active Active
- 2019-12-20 JP JP2021535554A patent/JP7773195B2/ja active Active
- 2019-12-20 CN CN201980092976.7A patent/CN113677351B/zh active Active
- 2019-12-20 CN CN202411342304.6A patent/CN119015448A/zh active Pending
- 2019-12-20 CA CA3123853A patent/CA3123853A1/en active Pending
- 2019-12-20 EP EP19899959.1A patent/EP3897669A4/en active Pending
- 2019-12-20 WO PCT/US2019/067890 patent/WO2020132465A1/en not_active Ceased
-
2025
- 2025-10-30 JP JP2025183107A patent/JP2026021440A/ja active Pending